FDA Approves WELIREG — SUPPL Submission by MERCK SHARP DOHME, Not disclosed in the FDA record.

Key facts

Regulatory context

This application was reviewed under FDA's priority review pathway, granted when a product may offer a significant improvement over existing treatments, which typically targets a 6-month review goal measured from submission. A New Drug Application (NDA) is the FDA pathway used to approve a brand-name drug for the first time. An NDA requires the sponsor to submit the full preclinical and clinical trial data package demonstrating the product's safety and effectiveness for its proposed use, along with manufacturing and labeling information. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements.

What was approved

FDA's record shows MERCK SHARP DOHME as the sponsor of WELIREG, with the generic name recorded as Not disclosed in the FDA record. and dosage form TABLET. A New Drug Application (NDA) is the FDA pathway used to approve a brand-name drug for the first time. An NDA requires the sponsor to submit the full preclinical and clinical trial data package demonstrating the product's safety and effectiveness for its proposed use, along with manufacturing and labeling information. This specific application is submission type SUPPL (submission number 15) under application number NDA215383, with a submission status date of 20260612. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

MERCK SHARP DOHME’s FDA history

Argus HQ has recorded 3 total FDA actions tied to MERCK SHARP DOHME: 0 warning letters, 0 recalls, 3 approval records, and 0 Form 483 inspection citations.

Frequently asked questions

What does the submission type mean?

A New Drug Application (NDA) is the FDA pathway used to approve a brand-name drug for the first time. An NDA requires the sponsor to submit the full preclinical and clinical trial data package demonstrating the product's safety and effectiveness for its proposed use, along with manufacturing and labeling information.

Is this product available now?

FDA's record lists a submission status date of 20260612. Availability, pricing, and distribution details beyond the submission status date are Not disclosed in the FDA record. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway.

Does MERCK SHARP DOHME have other FDA approval records?

Yes. Argus HQ has recorded 3 total FDA actions tied to MERCK SHARP DOHME, including 3 approval records.

What is the FDA application number for this submission?

FDA application number NDA215383, submission 15.

Related enforcement actions